{"name":"Genenta Science","slug":"genenta","ticker":"GNTA.MI","exchange":"Euronext Milan","domain":"genenta.com","description":"Genenta Science is a biotech company focused on gene therapy and immuno-oncology. The company is developing treatments for various diseases, including glioblastoma and other cancers. Genenta Science has a pipeline of promising candidates, including its lead product, GTI-204009. The company is headquartered in Italy and is listed on the Italian Stock Exchange.","hq":"Milan, Italy","founded":0,"employees":"","ceo":"Pierluigi Paracchi","sector":"Gene Therapy / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$55M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"GTI-204009 patent cliff ($0.0B at risk)","drug":"GTI-204009","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Temferon","genericName":"Temferon","slug":"temferon","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Temferon","genericName":"Temferon","slug":"temferon","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Genenta Science Reports Q4 2023 Earnings","summary":"Genenta Science reported its Q4 2023 earnings, with a net loss of €10.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Genenta Science Partners with Leading Research Institution","summary":"Genenta Science partnered with a leading research institution to advance its gene therapy research.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"GTI-204009","drugSlug":"gti-204009","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novartis","Roche","Bayer"],"therapeuticFocus":["Gene Therapy","Immuno-Oncology"],"financials":null,"yahoo":null}